{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:34:52Z","timestamp":1793637292829,"version":"4.5.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-02024-7","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:13:27Z","timestamp":1748852007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care"],"prefix":"10.1186","volume":"27","author":[{"given":"Hai-Jing","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiao","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"2024_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2024_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1158\/1078-0432.ccr-16-0825","volume":"23","author":"JA Shaw","year":"2017","unstructured":"Shaw JA, Guttery DS, Hills A, Fernandez-Garcia D, Page K, Rosales BM, Goddard KS, Hastings RK, Luo J, Ogle O, et al. Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high circulating tumor cell counts. Clin Cancer Res. 2017;23:88\u201396. https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-0825.","journal-title":"Clin Cancer Res"},{"key":"2024_CR3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrclinonc.2013.101","volume":"10","author":"M Basik","year":"2013","unstructured":"Basik M, Aguilar-Mahecha A, Rousseau C, Diaz Z, Tejpar S, Spatz A, Greenwood CMT, Batist G. Biopsies: next-generation biospecimens for tailoring therapy. Nat Rev Clin Oncol. 2013;10:437\u201350. https:\/\/doi.org\/10.1038\/nrclinonc.2013.101.","journal-title":"Nat Rev Clin Oncol"},{"key":"2024_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12885-018-4115-1","volume":"18","author":"H Huebner","year":"2018","unstructured":"Huebner H, Fasching PA, Gumbrecht W, Jud S, Rauh C, Matzas M, Paulicka P, Friedrich K, Lux MP, Volz B, et al. Filtration based assessment of CTCs and Cell Search\u00ae based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. BMC Cancer. 2018;18:204. https:\/\/doi.org\/10.1186\/s12885-018-4115-1.","journal-title":"BMC Cancer"},{"key":"2024_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-022-06585-5","volume":"193","author":"L Dirix","year":"2022","unstructured":"Dirix L, Buys A, Oeyen S, Peeters D, Li\u00e8geois V, Prov\u00e9 A, Rondas D, Vervoort L, Mari\u00ebn V, Laere SV, et al. Circulating tumor cell detection: a prospective comparison between Cell Search\u00ae and RareCyte\u00ae platforms in patients with progressive metastatic breast cancer. Breast Cancer Res Treat. 2022;193:437\u201344. https:\/\/doi.org\/10.1007\/s10549-022-06585-5.","journal-title":"Breast Cancer Res Treat"},{"key":"2024_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1186\/s12885-024-12818-1","volume":"24","author":"L Wang","year":"2024","unstructured":"Wang L, Hong R, Shi S, Wang S, Chen Y, Han C, Li M, Ye F. The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer. BMC Cancer. 2024;24:1067. https:\/\/doi.org\/10.1186\/s12885-024-12818-1.","journal-title":"BMC Cancer"},{"key":"2024_CR7","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/clinchem\/hvac127","volume":"68","author":"A Darlix","year":"2022","unstructured":"Darlix A, Cayrefourcq L, Pouderoux S, Menjot N, de Champfleur A, Bievelez WJ, Leaha C, Thezenas S, Alix-Panabi\u00e8res C. Detection of circulating tumor cells in cerebrospinal fluid of patients with suspected breast cancer leptomeningeal metastases: a prospective study. Clin Chem. 2022;68:1311\u201322. https:\/\/doi.org\/10.1093\/clinchem\/hvac127.","journal-title":"Clin Chem"},{"key":"2024_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13046-024-03149-x","volume":"43","author":"M Ciccioli","year":"2024","unstructured":"Ciccioli M, Kim K, Khazan N, Khoury JD, Cooke MJ, Miller MC, O\u2019Shannessy DJ, Pailhes-Jimenez A-S, Moore RG. Identification of circulating tumor cells captured by the FDA-cleared Parsortix\u00ae PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations. J Exp Clin Cancer Res. 2024;43:240. https:\/\/doi.org\/10.1186\/s13046-024-03149-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"2024_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs22-p1-05-35","author":"M Ciccioli","year":"2023","unstructured":"Ciccioli M, Moore R, Kim KK, Khazan N, Miller MC, Pailhes-Jimenez A-S. Identification of circulating tumor cells captured by the FDA cleared parsortix\u00ae PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs22-p1-05-35.","journal-title":"Cancer Res"},{"key":"2024_CR10","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs22-p5-06-01","author":"E Cohen","year":"2023","unstructured":"Cohen E, Jayachandran G, Moore R, Cristofanilli M, Lang JE, Khoury J, Press MF, McBride H, Kim KK, Khazan N, et al. A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the parsortix\u00ae PC1 system in support of FDA clearance. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs22-p5-06-01.","journal-title":"Cancer Res"},{"key":"2024_CR11","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1538-7445.Am2024-3705","volume":"84","author":"M Ciccioli","year":"2024","unstructured":"Ciccioli M, Young A, Vlietinck L, Johnson C, Pailhes-Jimenez A-S. Development and analytical validation of a novel assay for HER2 assessment on circulating tumor cells using Parsortix\u00ae isolation and BioView imaging technologies. Cancer Res. 2024;84:3705. https:\/\/doi.org\/10.1158\/1538-7445.Am2024-3705.","journal-title":"Cancer Res"},{"key":"2024_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3390\/cancers12051134","volume":"12","author":"S Miklikova","year":"2020","unstructured":"Miklikova S, Minarik G, Sedlackova T, Plava J, Cihova M, Jurisova S, Kalavska K, Karaba M, Benca J, Smolkova B, et al. Inflammation-based scores increase the prognostic value of circulating tumor cells in primary breast cancer. Cancers. 2020;12:1134.","journal-title":"Cancers"},{"key":"2024_CR13","doi-asserted-by":"publisher","first-page":"18195","DOI":"10.1038\/s41598-019-54839-y","volume":"9","author":"M Hattori","year":"2019","unstructured":"Hattori M, Nakanishi H, Yoshimura M, Iwase M, Yoshimura A, Adachi Y, Gondo N, Kotani H, Sawaki M, Fujita N, et al. Circulating tumor cells detection in tumor draining vein of breast cancer patients. Sci Rep. 2019;9:18195. https:\/\/doi.org\/10.1038\/s41598-019-54839-y.","journal-title":"Sci Rep"},{"key":"2024_CR14","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1021\/acssensors.9b02537","volume":"5","author":"X Li","year":"2020","unstructured":"Li X, Zhang P, Dou L, Wang Y, Sun K, Zhang X, Song G, Zhao C, Li K, Bai Y, et al. Detection of circulating tumor cells in breast cancer patients by nanopore sensing with aptamer-mediated amplification. ACS Sensors. 2020;5:2359\u201366. https:\/\/doi.org\/10.1021\/acssensors.9b02537.","journal-title":"ACS Sensors"},{"key":"2024_CR15","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1039\/D0SC05112H","volume":"12","author":"W Xia","year":"2021","unstructured":"Xia W, Shangguan X, Li M, Wang Y, Xi D, Sun W, Fan J, Shao K, Peng X. Ex vivo identification of circulating tumor cells in peripheral blood by fluorometric \u201cturn on\u201d aptamer nanoparticles. Chem Sci. 2021;12:3314\u201321. https:\/\/doi.org\/10.1039\/D0SC05112H.","journal-title":"Chem Sci"},{"key":"2024_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12967-020-02237-8","volume":"18","author":"J Chen","year":"2020","unstructured":"Chen J, Ye C, Dong J, Cao S, Hu Y, Situ B, Xi X, Qin S, Xu J, Cai Z, et al. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. J Transl Med. 2020;18:59. https:\/\/doi.org\/10.1186\/s12967-020-02237-8.","journal-title":"J Transl Med"},{"key":"2024_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fonc.2015.00042","volume":"5","author":"LM McInnes","year":"2015","unstructured":"McInnes LM, Jacobson N, Redfern A, Dowling A, Thompson EW, Saunders CM. Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol. 2015;5:42. https:\/\/doi.org\/10.3389\/fonc.2015.00042.","journal-title":"Front Oncol"},{"key":"2024_CR18","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","volume":"6","author":"M Radovich","year":"2020","unstructured":"Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, Lynce FC, Gallagher C, Isaacs C, Blaya M, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial. JAMA Oncol. 2020;6:1410\u20135. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2295.","journal-title":"JAMA Oncol"},{"key":"2024_CR19","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/1078-0432.ccr-17-1181","volume":"24","author":"S Mastoraki","year":"2018","unstructured":"Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E. ESR1 Methylation: a liquid biopsy-based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment. Clin Cancer Res. 2018;24:1500\u201310. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-1181.","journal-title":"Clin Cancer Res"},{"key":"2024_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03462-0","author":"AFC Okines","year":"2025","unstructured":"Okines AFC, Curigliano G, Mizuno N, Oh D-Y, Rorive A, Soliman H, Takahashi S, Bekaii-Saab T, Burkard ME, Chung KY, et al. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-024-03462-0.","journal-title":"Nat Med"},{"key":"2024_CR21","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.1038\/s41467-022-35245-x","volume":"13","author":"S Sivakumar","year":"2022","unstructured":"Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, et al. Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nat Commun. 2022;13:7495. https:\/\/doi.org\/10.1038\/s41467-022-35245-x.","journal-title":"Nat Commun"},{"key":"2024_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41698-024-00544-7","volume":"8","author":"D Vasseur","year":"2024","unstructured":"Vasseur D, Arbab A, Giudici F, Marzac C, Michiels S, Tagliamento M, Bayle A, Smolenschi C, Sakkal M, Aldea M, et al. Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients. npj Precis Oncol. 2024;8:51. https:\/\/doi.org\/10.1038\/s41698-024-00544-7.","journal-title":"npj Precis Oncol"},{"key":"2024_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103687","volume":"9","author":"R Cutts","year":"2024","unstructured":"Cutts R, Ulrich L, Beaney M, Robert M, Coakley M, Bunce C, Crestani GW, Hrebien S, Kalashnikova E, Wu HT, et al. Association of post-operative ctDNA detection with outcomes of patients with early breast cancers. ESMO Open. 2024;9: 103687. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103687.","journal-title":"ESMO Open"},{"key":"2024_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00456","author":"JA Shaw","year":"2024","unstructured":"Shaw JA, Page K, Wren E, Bruin ECd, Kalashnikova E, Hastings R, McEwen R, Zhang E, Wadsley M, Acheampong E, et al. Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/po.23.00456.","journal-title":"JCO Precis Oncol"},{"key":"2024_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs22-p5-05-05","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Rugo H, Swigart LAB, Ahmed Z, Hirst GL, Wolf DM, Lu R, Kalashnikova E, Renner D, Rodriguez A, et al. Abstract P5\u201305\u201305: Monitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating tumor DNA testing. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs22-p5-05-05.","journal-title":"Cancer Res"},{"key":"2024_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.clbc.2016.05.004","volume":"16","author":"C Nakauchi","year":"2016","unstructured":"Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, Shimoda M, Kim SJ, Noguchi S. Detection of TP53\/PIK3CA mutations in cell-free plasma DNA from metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer. 2016;16:418\u201323. https:\/\/doi.org\/10.1016\/j.clbc.2016.05.004.","journal-title":"Clin Breast Cancer"},{"key":"2024_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10549-023-06967-3","volume":"201","author":"TW-W Chen","year":"2023","unstructured":"Chen TW-W, Hsiao W, Dai M-S, Lin C-H, Chang D-Y, Chen IC, Wang M-Y, Chang S-H, Huang S-M, Cheng A-L, et al. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer. Breast Cancer Res Tr. 2023;201:377\u201385. https:\/\/doi.org\/10.1007\/s10549-023-06967-3.","journal-title":"Breast Cancer Res Tr"},{"key":"2024_CR28","doi-asserted-by":"publisher","first-page":"6494","DOI":"10.18632\/oncotarget.27303","volume":"10","author":"J Mijnes","year":"2019","unstructured":"Mijnes J, Tiedemann J, Eschenbruch J, Gasthaus J, Bringezu S, Bauerschlag D, Maass N, Arnold N, Weimer J, Anzeneder T, et al. SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. Oncotarget. 2019;10:6494\u2013508. https:\/\/doi.org\/10.18632\/oncotarget.27303.","journal-title":"Oncotarget"},{"key":"2024_CR29","doi-asserted-by":"publisher","DOI":"10.1272\/jnms.JNMS.2022_89-107","author":"M Nakai","year":"2021","unstructured":"Nakai M, Yamada T, Sekiya K, Sato A, Hankyo M, Kuriyama S, Takahashi G, Kurita T, Yanagihara K, Yoshida H, et al. PIK3CA mutation detected by liquid biopsy in patients with metastatic breast cancer. JNMS. 2021. https:\/\/doi.org\/10.1272\/jnms.JNMS.2022_89-107.","journal-title":"JNMS"},{"key":"2024_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41523-018-0093-3","volume":"4","author":"S Kumar","year":"2018","unstructured":"Kumar S, Lindsay D, Chen QB, Garrett AL, Tan XM, Anders CK, Carey LA, Gupta GP. Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. npj Breast Cancer. 2018;4:39. https:\/\/doi.org\/10.1038\/s41523-018-0093-3.","journal-title":"npj Breast Cancer"},{"key":"2024_CR31","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1002\/1878-0261.13592","volume":"18","author":"J Corn\u00e9","year":"2024","unstructured":"Corn\u00e9 J, Quillien V, Godey F, Cherel M, Cochet A, Le Du F, Robert L, Bourien H, Brunot A, Crouzet L, et al. Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer. Mol Oncol. 2024;18:2714\u201329. https:\/\/doi.org\/10.1002\/1878-0261.13592.","journal-title":"Mol Oncol"},{"key":"2024_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12943-023-01715-z","volume":"22","author":"S Ma","year":"2023","unstructured":"Ma S, Zhou M, Xu Y, Gu X, Zou M, Abudushalamu G, Yao Y, Fan X, Wu G. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023;22:7. https:\/\/doi.org\/10.1186\/s12943-023-01715-z.","journal-title":"Mol Cancer"},{"key":"2024_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10549-020-05596-4","volume":"181","author":"A Gennari","year":"2020","unstructured":"Gennari A, Foca F, Zamarchi R, Rocca A, Amadori D, De Censi A, Bologna A, Cavanna L, Gianni L, Scaltriti L, et al. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Res Tr. 2020;181:61\u20138. https:\/\/doi.org\/10.1007\/s10549-020-05596-4.","journal-title":"Breast Cancer Res Tr"},{"key":"2024_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41523-021-00218-8","volume":"7","author":"O Mart\u00ednez-S\u00e1ez","year":"2021","unstructured":"Mart\u00ednez-S\u00e1ez O, Pascual T, Bras\u00f3-Maristany F, Chic N, Gonz\u00e1lez-Farr\u00e9 B, Sanfeliu E, Rodr\u00edguez A, Mart\u00ednez D, Galv\u00e1n P, Rodr\u00edguez AB, et al. Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4\/6 inhibition and endocrine therapy. npj Breast Cancer. 2021;7:8. https:\/\/doi.org\/10.1038\/s41523-021-00218-8.","journal-title":"npj Breast Cancer"},{"key":"2024_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41523-024-00642-6","volume":"10","author":"A Alba-Bernal","year":"2024","unstructured":"Alba-Bernal A, Godoy-Ortiz A, Dom\u00ednguez-Recio ME, L\u00f3pez-L\u00f3pez E, Quir\u00f3s-Ortega ME, S\u00e1nchez-Mart\u00edn V, Rold\u00e1n-D\u00edaz MD, Jim\u00e9nez-Rodr\u00edguez B, Peralta-Linero J, Bellagarza-Garc\u00eda E, et al. Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients. npj Breast Cancer. 2024;10:36. https:\/\/doi.org\/10.1038\/s41523-024-00642-6.","journal-title":"npj Breast Cancer"},{"key":"2024_CR36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmoldx.2019.11.006","volume":"22","author":"SN Shishido","year":"2020","unstructured":"Shishido SN, Welter L, Rodriguez-Lee M, Kolatkar A, Xu L, Ruiz C, Gerdtsson AS, Restrepo-Vassalli S, Carlsson A, Larsen J, et al. Preanalytical variables for the genomic assessment of the cellular and acellular fractions of the liquid biopsy in a cohort of breast cancer patients. J Mol Diagn. 2020;22:319\u201337. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.11.006.","journal-title":"J Mol Diagn"},{"key":"2024_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051111","author":"C Costa","year":"2020","unstructured":"Costa C, Muinelo-Romay L, Cebey-L\u00f3pez V, Pereira-Veiga T. Analysis of a real-world cohort of metastatic breast cancer patients shows circulating tumor cell clusters (CTC-clusters) as predictors of patient outcomes. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12051111.","journal-title":"Cancers"},{"key":"2024_CR38","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, Zhu F, Zhou D, Zheng S, Chen Y, et al. Circulating tumor cells: biology and clinical significance. STTT. 2021;6:404. https:\/\/doi.org\/10.1038\/s41392-021-00817-8.","journal-title":"STTT"},{"key":"2024_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12935-019-1067-8","volume":"19","author":"C Yang","year":"2019","unstructured":"Yang C, Xia B-R, Jin W-L, Lou G. Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model. Cancer Cell Int. 2019;19:341. https:\/\/doi.org\/10.1186\/s12935-019-1067-8.","journal-title":"Cancer Cell Int"},{"key":"2024_CR40","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.cd-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11:858\u201373. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1311.","journal-title":"Cancer Discov"},{"key":"2024_CR41","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","volume":"30","author":"G Siravegna","year":"2019","unstructured":"Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, et al. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019;30:1580\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdz227.","journal-title":"Ann Oncol"},{"key":"2024_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-020-01298-z","volume":"20","author":"S Wang","year":"2021","unstructured":"Wang S, Zhang K, Tan S, Xin J, Yuan Q, Xu H, Xu X, Liang Q, Christiani DC, Wang M, et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. Mol Cancer. 2021;20:13. https:\/\/doi.org\/10.1186\/s12943-020-01298-z.","journal-title":"Mol Cancer"},{"key":"2024_CR43","doi-asserted-by":"publisher","first-page":"7694","DOI":"10.1038\/s41467-022-35320-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Cheng Z, Dong M, Liu Q, Yang W, Liu M, Tian J, Cheng W. Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis. Nat Commun. 2022;13:7694. https:\/\/doi.org\/10.1038\/s41467-022-35320-3.","journal-title":"Nat Commun"},{"key":"2024_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13073-021-00895-x","volume":"13","author":"ZT Weber","year":"2021","unstructured":"Weber ZT, Collier KA, Tallman D, Forman J, Shukla S, Asad S, Rhoades J, Freeman S, Parsons HA, Williams NO, et al. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer. Genome Med. 2021;13:89. https:\/\/doi.org\/10.1186\/s13073-021-00895-x.","journal-title":"Genome Med"},{"key":"2024_CR45","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/s41467-023-36801-9","volume":"14","author":"A Prat","year":"2023","unstructured":"Prat A, Bras\u00f3-Maristany F, Mart\u00ednez-S\u00e1ez O, Sanfeliu E, Xia Y, Bellet M, Galv\u00e1n P, Mart\u00ednez D, Pascual T, Mar\u00edn-Aguilera M, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nat Commun. 2023;14:1157. https:\/\/doi.org\/10.1038\/s41467-023-36801-9.","journal-title":"Nat Commun"},{"key":"2024_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","volume":"34","author":"ZR Reichert","year":"2023","unstructured":"Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall\u2019Olio FG, Madison RW, Fine AD, Oxnard GR, Graf RP, et al. Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol. 2023;34:111\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.163.","journal-title":"Ann Oncol"},{"key":"2024_CR47","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs23-po5-14-05","author":"NL Shan","year":"2024","unstructured":"Shan NL, Gould B, Blenman K, Foldi J, Du P, Zhang F, Walsh M, Pusztai L. Abstract PO5\u201314\u201305: circulating tumor DNA fraction correlates with residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer patients. Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-po5-14-05.","journal-title":"Cancer Res"},{"key":"2024_CR48","doi-asserted-by":"publisher","first-page":"eaax7392","DOI":"10.1126\/scitranslmed.aax7392","volume":"11","author":"BR McDonald","year":"2019","unstructured":"McDonald BR, Contente-Cuomo T, Sammut S-J, Odenheimer-Bergman A, Ernst B, Perdigones N, Chin S-F, Farooq M, Mejia R, Cronin PA, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Trans Med. 2019;11:eaax7392. https:\/\/doi.org\/10.1126\/scitranslmed.aax7392.","journal-title":"Sci Trans Med"},{"key":"2024_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","volume":"10","author":"F Panet","year":"2024","unstructured":"Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential. npj Breast Cancer. 2024;10:50. https:\/\/doi.org\/10.1038\/s41523-024-00653-3.","journal-title":"npj Breast Cancer"},{"key":"2024_CR50","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo B, Wu A, Wetterskog D, Attard G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br J Cancer. 2022;127:1394\u2013402. https:\/\/doi.org\/10.1038\/s41416-022-01881-9.","journal-title":"Br J Cancer"},{"key":"2024_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2023.100014","author":"I Silverman","year":"2023","unstructured":"Silverman I, Schonhoft J, Yablonovitch A, Lagow E, Cecchini M, Herzberg B, Reis-Filho J, Rosen E, Rimkunas V, Yap T. Performance of circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) in the TRESR and ATTACC studies. J Liq Biopsy. 2023. https:\/\/doi.org\/10.1016\/j.jlb.2023.100014.","journal-title":"J Liq Biopsy"},{"key":"2024_CR52","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1200\/JCO.2024.42.16_suppl.1042","volume":"42","author":"LM Linville","year":"2024","unstructured":"Linville LM, Canzoniero JV, Too F, Lombardo A, Malwankar J, Mawalkar R, Haile M, Zandi L, Babu V, Brown DW, et al. Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer. J Clin Oncol. 2024;42:1042. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1042.","journal-title":"J Clin Oncol"},{"key":"2024_CR53","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1200\/JCO.2024.42.16_suppl.3129","volume":"42","author":"D Liu","year":"2024","unstructured":"Liu D, Keller-Evans RB, Schrock AB, Drilon AE, Jee J, Li BT. Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors. J Clin Oncol. 2024;42:3129. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.3129.","journal-title":"J Clin Oncol"},{"key":"2024_CR54","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","volume":"207","author":"MA Bhave","year":"2024","unstructured":"Bhave MA, Quintanilha JCF, Tukachinsky H, Li G, Scott T, Ross JS, Pasquina L, Huang RSP, McArthur H, Levy MA, et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Tr. 2024;207:599\u2013609. https:\/\/doi.org\/10.1007\/s10549-024-07376-w.","journal-title":"Breast Cancer Res Tr"},{"key":"2024_CR55","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Sabcs23-po2-16-03","author":"H McArthur","year":"2024","unstructured":"McArthur H, Tukachinsky H, Schrock A, Madison R, Holmes O, Sivakumar S, Sokol E, Graf R, Quintanilha J, Dougherty K, et al. Abstract PO2\u201316\u201303: ESR1 genomic alterations (GAs) and coexistent putative resistance alterations in comprehensive genomic profiling (CGP) of metastatic breast cancer (MBC). Cancer Res. 2024. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs23-po2-16-03.","journal-title":"Cancer Res"},{"key":"2024_CR56","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00261","author":"H Husain","year":"2022","unstructured":"Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, Parachoniak CA, McLaughlin-Drubin M, Erlich RL, Schrock AB, et al. Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples. JCO Precis Oncol. 2022. https:\/\/doi.org\/10.1200\/po.22.00261.","journal-title":"JCO Precis Oncol"},{"key":"2024_CR57","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/1878-0261.13557","volume":"18","author":"E Kalashnikova","year":"2024","unstructured":"Kalashnikova E, Aushev VN, Malashevich AK, Tin A, Krinshpun S, Salari R, Scalise CB, Ram R, Malhotra M, Ravi H, et al. Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors. Mol Oncol. 2024;18:2649\u201357. https:\/\/doi.org\/10.1002\/1878-0261.13557.","journal-title":"Mol Oncol"},{"key":"2024_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41698-021-00202-2","volume":"5","author":"JD Finkle","year":"2021","unstructured":"Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, Khan AA, Lozac\u2019hmeur A, McKinnon KE, Perera J, et al. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. npj Precis Oncol. 2021;5:63. https:\/\/doi.org\/10.1038\/s41698-021-00202-2.","journal-title":"npj Precis Oncol."},{"key":"2024_CR59","doi-asserted-by":"publisher","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","volume":"7","author":"WT Iams","year":"2024","unstructured":"Iams WT, Mackay M, Ben-Shachar R, Drews J, Manghnani K, Hockenberry AJ, Cristofanilli M, Nimeiri H, Guinney J, Benson AB. Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort. JAMA Netw Open. 2024;7:e2351700. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.51700.","journal-title":"JAMA Netw Open"},{"key":"2024_CR60","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1078-0432.Ccr-24-2396","volume":"31","author":"Y Nakamura","year":"2025","unstructured":"Nakamura Y, Kaneva K, Lo C, Neems D, Freaney JE, Boulos H, Hyun SW, Islam F, Yamada-Hanff J, Driessen TM, et al. A tumor-na\u00efve ctDNA assay detects minimal residual disease in resected stage II or III colorectal cancer and predicts recurrence: subset analysis from the GALAXY study in CIRCULATE-Japan. Clin Cancer Res. 2025;31:328\u201338. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-2396.","journal-title":"Clin Cancer Res"},{"key":"2024_CR61","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1158\/1538-7445.Am2024-3676","volume":"84","author":"MM Stein","year":"2024","unstructured":"Stein MM, Kaneva K, Hyun SW, Sangli C, Ting-Lin M, Ben-Shachar R, Freaney J, Sasser K, Guinney J, Nimeiri H, et al. Abstract 3676: a circulating tumor fraction DNA biomarker response stratified by ESR1 mutation status correlates with overall survival in patients with HR+ HER2- metastatic breast cancer. Cancer Res. 2024;84:3676. https:\/\/doi.org\/10.1158\/1538-7445.Am2024-3676.","journal-title":"Cancer Res"},{"key":"2024_CR62","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"F-C Bidard","year":"2022","unstructured":"Bidard F-C, Hardy-Bessard A-C, Dalenc F, Bachelot T, Pierga J-Y, de la Motte RT, Sabatier R, Dubot C, Frenel J-S, Ferrero JM, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising <em>ESR1<\/em> mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23:1367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1.","journal-title":"Lancet Oncol"},{"key":"2024_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13058-018-0976-0","volume":"20","author":"A-M Larsson","year":"2018","unstructured":"Larsson A-M, Jansson S, Bendahl P-O, Levin Tykjaer J\u00f6rgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K, Ryd\u00e9n L. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Br Cancer Res. 2018;20:48. https:\/\/doi.org\/10.1186\/s13058-018-0976-0.","journal-title":"Br Cancer Res"},{"key":"2024_CR64","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3390\/cells9071718","volume":"9","author":"U Narbe","year":"2020","unstructured":"Narbe U, Bendahl P-O, Aaltonen K, Fern\u00f6 M, Forsare C, J\u00f8rgensen CLT, Larsson A-M, Ryd\u00e9n L. The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast\u2014long-term prognostic significance. Cells. 2020;9:1718.","journal-title":"Cells"},{"key":"2024_CR65","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3390\/cancers12051111","volume":"12","author":"C Costa","year":"2020","unstructured":"Costa C, Muinelo-Romay L, Cebey-L\u00f3pez V, Pereira-Veiga T, Mart\u00ednez-Pena I, Abreu M, Abalo A, Lago-Lest\u00f3n RM, Abu\u00edn C, Palacios P, et al. Analysis of a real-world cohort of metastatic breast cancer patients shows circulating tumor cell clusters (CTC-clusters) as predictors of patient outcomes. Cancers. 2020;12:1111.","journal-title":"Cancers"},{"key":"2024_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/adsr.202300206","author":"A Hassanzadeh-Barforoushi","year":"2024","unstructured":"Hassanzadeh-Barforoushi A, Tsao SC-H, Nadalini A, Inglis DW, Wang Y. Rapid isolation and detection of breast cancer circulating tumor cells using microfluidic sequential trapping array. Adv Sens Res. 2024. https:\/\/doi.org\/10.1002\/adsr.202300206.","journal-title":"Adv Sens Res"},{"key":"2024_CR67","doi-asserted-by":"publisher","first-page":"15980","DOI":"10.1038\/srep15980","volume":"5","author":"C Gasch","year":"2015","unstructured":"Gasch C, Plummer PN, Jovanovic L, McInnes LM, Wescott D, Saunders CM, Schneeweiss A, Wallwiener M, Nelson C, Spring KJ, et al. Heterogeneity of miR-10b expression in circulating tumor cells. Sci Rep. 2015;5:15980. https:\/\/doi.org\/10.1038\/srep15980.","journal-title":"Sci Rep"},{"key":"2024_CR68","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamaoncol.2020.5660","volume":"7","author":"F-C Bidard","year":"2021","unstructured":"Bidard F-C, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, Bachelot T, Bourgeois H, Gon\u00e7alves A, Ladoire S, et al. Efficacy of circulating tumor cell count-driven versus clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol. 2021;7:34\u201341. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5660.","journal-title":"JAMA Oncol"},{"key":"2024_CR69","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553\u201367. https:\/\/doi.org\/10.1038\/s41568-019-0180-2.","journal-title":"Nat Rev Cancer"},{"key":"2024_CR70","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","volume":"4","author":"J Sparano","year":"2018","unstructured":"Sparano J, O\u2019Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, Sledge GW, Miller KD. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:1700\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2574.","journal-title":"JAMA Oncol"},{"key":"2024_CR71","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/annonc\/mdy544","volume":"30","author":"J Seoane","year":"2019","unstructured":"Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019;30:211\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy544.","journal-title":"Ann Oncol"},{"key":"2024_CR72","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1:276\u201390. https:\/\/doi.org\/10.1038\/s43018-020-0043-5.","journal-title":"Nat Cancer"},{"key":"2024_CR73","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.ccr-20-4805","volume":"27","author":"H Tukachinsky","year":"2021","unstructured":"Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin Cancer Res. 2021;27:3094\u2013105. https:\/\/doi.org\/10.1158\/1078-0432.ccr-20-4805.","journal-title":"Clin Cancer Res"},{"key":"2024_CR74","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/jcm8081183","volume":"8","author":"B Jimenez Rodriguez","year":"2019","unstructured":"Jimenez Rodriguez B, Diaz C\u00f3rdoba G, Garrido Aranda A, \u00c1lvarez M, Vicioso L, Ll\u00e1cer P\u00e9rez C, Hernando C, Bermejo B, Julve Parre\u00f1o A, Lluch A, et al. Detection of TP53 and PIK3CA mutations in circulating tumor DNA using next-generation sequencing in the screening process for early breast cancer diagnosis. J Clin Med. 2019;8:1183.","journal-title":"J Clin Med"},{"key":"2024_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2016.03.001","volume":"382","author":"G Judes","year":"2016","unstructured":"Judes G, Rifa\u00ef K, Daures M, Dubois L, Bignon Y-J, Penault-Llorca F, Bernard-Gallon D. High-throughput \u00abOmics\u00bb technologies: new tools for the study of triple-negative breast cancer. Cancer Lett. 2016;382:77\u201385. https:\/\/doi.org\/10.1016\/j.canlet.2016.03.001.","journal-title":"Cancer Lett"},{"key":"2024_CR76","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","volume":"34","author":"NC Turner","year":"2023","unstructured":"Turner NC, Swift C, Jenkins B, Kilburn L, Coakley M, Beaney M, Fox L, Goddard K, Garcia-Murillas I, Proszek P, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023;34:200\u201311. https:\/\/doi.org\/10.1016\/j.annonc.2022.11.005.","journal-title":"Ann Oncol"},{"key":"2024_CR77","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.Ccr-23-3321","volume":"30","author":"CD Rolfo","year":"2024","unstructured":"Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, Graf RP, Oxnard GR, Husain H. Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation. Clin Cancer Res. 2024;30:2452\u201360. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-3321.","journal-title":"Clin Cancer Res"},{"key":"2024_CR78","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1158\/1078-0432.ccr-23-0956","volume":"29","author":"J Pascual","year":"2023","unstructured":"Pascual J, Gil-Gil M, Proszek P, Zielinski C, Reay A, Ruiz-Borrego M, Cutts R, Ciruelos Gil EM, Feber A, Mu\u00f1oz-Mateu M, et al. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients. Clin Cancer Res. 2023;29:4166\u201377. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-0956.","journal-title":"Clin Cancer Res"},{"key":"2024_CR79","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12916-023-03017-z","volume":"21","author":"J Chiu","year":"2023","unstructured":"Chiu J, Su F, Joshi M, Masuda N, Ishikawa T, Aruga T, Zarate JP, Babbar N, Balbin OA, Yap Y-S. Potential value of ctDNA monitoring in metastatic HR+ \/HER2\u2212 breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. BMC Med. 2023;21:306. https:\/\/doi.org\/10.1186\/s12916-023-03017-z.","journal-title":"BMC Med"},{"key":"2024_CR80","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13058-020-1246-5","volume":"22","author":"A Zundelevich","year":"2020","unstructured":"Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, Cesarkas K, Farage-Barhom S, Saar EG, Eyal E, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22:16. https:\/\/doi.org\/10.1186\/s13058-020-1246-5.","journal-title":"Breast Cancer Res"},{"key":"2024_CR81","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","volume":"34","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, Tripathy D, Lu YS, Lteif A, et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023;34:1003\u201314. https:\/\/doi.org\/10.1016\/j.annonc.2023.08.011.","journal-title":"Ann Oncol"},{"key":"2024_CR82","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1158\/1078-0432.ccr-23-0956","volume":"29","author":"J Pascual","year":"2023","unstructured":"Pascual J, Gil-Gil M. Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients. Clin Cancer Res. 2023;29:4166\u201377. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-0956.","journal-title":"Clin Cancer Res"},{"key":"2024_CR83","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, et al. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023;41:1091-102.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.04.008.","journal-title":"Cancer Cell"},{"key":"2024_CR84","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","volume":"9","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Hrebien S, Morden JP, Beaney M, Fribbens C, Huang X, Liu Y, Bartlett CH, Koehler M, Cristofanilli M, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9:896. https:\/\/doi.org\/10.1038\/s41467-018-03215-x.","journal-title":"Nat Commun"},{"key":"2024_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2022.100259","author":"Q Gao","year":"2022","unstructured":"Gao Q, Zeng Q, Wang Z, Li C, Xu Y, Cui P, Zhu X, Lu H, Wang G, Cai S, et al. Circulating cell-free DNA for cancer early detection. Innovation. 2022. https:\/\/doi.org\/10.1016\/j.xinn.2022.100259.","journal-title":"Innovation"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-02024-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-02024-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T08:13:28Z","timestamp":1748852008000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-02024-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-02024-7","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}